State Street Corp Has $3.30 Million Holdings in DURECT Corporation (DRRX)

State Street Corp grew its position in DURECT Corporation (NASDAQ:DRRX) by 10.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,117,618 shares of the specialty pharmaceutical company’s stock after purchasing an additional 193,734 shares during the period. State Street Corp owned about 1.44% of DURECT worth $3,303,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Mangrove Partners acquired a new stake in shares of DURECT during the second quarter worth $530,000. Stonepine Capital Management LLC raised its holdings in shares of DURECT by 13.4% during the second quarter. Stonepine Capital Management LLC now owns 3,175,994 shares of the specialty pharmaceutical company’s stock worth $4,955,000 after acquiring an additional 374,618 shares during the period. Voya Investment Management LLC raised its holdings in shares of DURECT by 22.8% during the second quarter. Voya Investment Management LLC now owns 82,826 shares of the specialty pharmaceutical company’s stock worth $129,000 after acquiring an additional 15,394 shares during the period. Vanguard Group Inc. raised its holdings in shares of DURECT by 3.3% during the second quarter. Vanguard Group Inc. now owns 5,368,184 shares of the specialty pharmaceutical company’s stock worth $8,374,000 after acquiring an additional 169,226 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of DURECT by 10.9% during the second quarter. Northern Trust Corp now owns 1,577,145 shares of the specialty pharmaceutical company’s stock worth $2,460,000 after acquiring an additional 154,640 shares during the period. Institutional investors own 44.69% of the company’s stock.

A number of brokerages recently commented on DRRX. Stifel Nicolaus lowered shares of DURECT from a “buy” rating to a “hold” rating in a report on Friday, October 20th. ValuEngine upgraded shares of DURECT from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. Laidlaw dropped their price objective on shares of DURECT from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, October 20th. Finally, HC Wainwright lowered shares of DURECT from a “buy” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a report on Friday, October 20th.

Shares of DURECT Corporation (NASDAQ DRRX) opened at $1.01 on Monday. DURECT Corporation has a twelve month low of $0.74 and a twelve month high of $2.17. The company has a current ratio of 1.67, a quick ratio of 1.57 and a debt-to-equity ratio of 1.46.

DURECT (NASDAQ:DRRX) last issued its quarterly earnings data on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.09. DURECT had a negative net margin of 62.57% and a negative return on equity of 419.65%. The business had revenue of $20.75 million for the quarter, compared to analyst estimates of $5.09 million. equities analysts expect that DURECT Corporation will post -0.14 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/11/state-street-corp-has-3-30-million-holdings-in-durect-corporation-drrx.html.

About DURECT

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Institutional Ownership by Quarter for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit